Enzyme source effects on CYP2C9 kinetics and inhibition

Area of Science:

• Biochemistry
• Pharmacology
• Drug Metabolism

Background:

• Recombinant cytochrome P450 (P450) enzyme systems are vital tools for in vitro drug metabolism studies.
• Variations in experimental conditions and bioanalytical methods across studies can confound comparisons of kinetic data.
• Understanding the limitations and applicability of different enzyme systems is critical for accurate study design.

Purpose of the Study:

• To compare the Michaelis-Menten kinetic parameters of four CYP2C9 substrates across four different recombinant CYP2C9 enzyme systems.
• To evaluate potential differences in metabolic product formation rates under standardized experimental conditions.
• To assess the impact of enzyme system choice on CYP2C9 inhibition studies.

Main Methods:

• Measured kinetic parameters (K(m), V(max)) for diclofenac, (S)-warfarin, tolbutamide, and (S)-flurbiprofen using Supersomes, Baculosomes, RECO system, and in-house purified enzyme.
• Assessed CYP2C9 inhibition using (S)-flurbiprofen as a substrate probe with 12 inhibitors.
• Utilized uniform experimental conditions and bioanalytical techniques for all enzyme systems.

Main Results:

• Purified, reconstituted enzyme systems showed higher K(m), lower substrate affinity, and reduced intrinsic clearance compared to baculovirus microsomal preparations.
• Six- to 25-fold differences in predicted intrinsic clearance were observed depending on the enzyme system and substrate.
• Eleven out of 12 inhibitors showed decreased potency in the RECO system compared to Supersomes and human liver microsomes.

Conclusions:

• Significant kinetic and inhibition differences exist among recombinant CYP2C9 enzyme systems.
• Enzyme system choice critically impacts the reliability and reproducibility of in vitro drug metabolism and inhibition data.
• Consistent use of a specific enzyme source is essential for generating comparable data in CYP2C9 research.